The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
Intravesical BCG therapy is effective in treating NMIBC, but it comes with side effects such as overactive bladder. As the duration of intravesical bacillus Calmette-Guérin (BCG) immunotherapy for ...
SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...
BCG therapy for NMIBC is associated with significant symptoms and side effects, but combining it with chemotherapy reduces these effects. BCG induction with maintenance is less toxic than induction ...
SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed. Across ...
Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results